Previous 10 | Next 10 |
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced the pricing of an underwritten public...
2023-10-30 18:18:26 ET More on Annovis Bio Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts Annovis Bio announces launch of proposed public offering Alzheimer's drug developers get lift from Anavex results Seeking Alpha’s Quant Rati...
2023-10-30 16:59:07 ET More on Annovis Bio Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts Alzheimer's drug developers get lift from Anavex results Seeking Alpha’s Quant Rating on Annovis Bio Historical earnings data for Annovis Bi...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced a proposed underwritten public offeri...
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients. The DSMB recommended that Annovis Bio continue the trial as ...
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Dis...
2023-10-16 19:10:54 ET Summary Annovis is expected to report data from Phase 3 and Phase 2/3 trials in Parkinson's and Alzheimer's disease, respectively. The efficacy of Annovis' lead compound, Buntanetap, is difficult to align with its proposed disease-modifying mechanism of acti...
2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...
2023-10-12 11:26:53 ET Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer’s acquisition of Seagen, Eli Lilly’s buyout of...
BERWYN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the independent statistical group concluded that its Phase 2/3 AD study was suffic...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...